Life sciences panel sees headwinds & opportunities in emerging US trade, drug pricing, FDA policies

As part of the Hogan Lovells Horizons 2025 life sciences event series, our cross-practice team recently met in Boston to discuss shifting regulatory paradigms under the Trump Administration, including trade, drug pricing, and regulatory reform. Our experts explored both the challenges and opportunities facing the industry, urging proactive engagement with U.S. regulators, particularly around tariffs, Most Favored Nation pricing models, and onshoring manufacturing. They highlighted the need for…
By: Hogan Lovells